Iowanews Headlines

DelveInsight’s, “Phenylketonuria Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Phenylketonuria pipeline landscape. It covers the Phenylketonuria pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Phenylketonuria pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Phenylketonuria Pipeline. Dive into DelveInsight’s comprehensive report today! @ Phenylketonuria Pipeline Outlook

Key Takeaways from the Phenylketonuria Pipeline Report

• On April 24, 2026- Otsuka Pharmaceutical Development & Commercialization Inc. announced a Phase 2 study is to assess the safety, tolerability, and pharmacokinetics (PK) of oral JNT-517 in adolescents (12 to less than 18 years of age) with PKU. Participants will receive either JNT-517 or placebo and will be blinded to their treatment assignment. Participants will have a 4 in 5 (or 80%) chance of receiving JNT-517. The study will last for up to 63 days including a Screening period, Treatment period and Follow-up period for safety.
• On April 24, 2026- PTC Therapeutics initiated a phase 3 study is to evaluate the long-term safety of PTC923 in participants with phenylketonuria, and to evaluate the changes from baseline in dietary phenylalanine (Phe)/protein consumption.
• DelveInsight’s Phenylketonuria pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Phenylketonuria treatment.
• The leading Phenylketonuria Companies such as Otsuka Pharmaceutical, Relief Therapeutics Holding, Next Generation Gene Therapeutics, BioMarin Pharmaceutical, Tessera Therapeutics, Maze Therapeutics, Agios Pharmaceuticals, Alltrna, iECURE, SOM Biotech, YolTech and others.
• Promising Phenylketonuria Pipeline Therapies such as Sepiapterin, PTC923, SYNB1618, SYNB1934, SAR444836, Kuvan®, Sapropterin dihydrochloride and others.

Stay ahead with the most recent pipeline outlook for Phenylketonuria @ Phenylketonuria Treatment Drugs

Phenylketonuria Overview

Phenylketonuria (PKU) is a rare inherited metabolic disorder caused primarily by mutations in the PAH gene, which lead to a deficiency or complete absence of the enzyme phenylalanine hydroxylase (PAH). This enzyme is essential for converting the amino acid phenylalanine into tyrosine, and without it, phenylalanine accumulates to toxic levels in the body, particularly affecting the brain. PKU is inherited in an autosomal recessive manner, meaning a child must inherit the defective gene from both parents to be affected. In rare cases, mutations affecting the cofactor tetrahydrobiopterin (BH4) or the DNAJC12 gene can also disrupt phenylalanine metabolism, resulting in related disorders. Newborns with PKU typically appear healthy at birth but, if left untreated, will begin to show signs such as intellectual disability, developmental delay, seizures, and behavioral issues within the first few months. Additional symptoms include hypopigmentation, a musty body odor, eczema, and in some cases, movement disorders. Adults with poorly managed PKU may suffer from cognitive decline, mood disorders, and challenges in social functioning. Early diagnosis through newborn screening and strict dietary management can prevent most severe complications, though symptom severity varies depending on the level of enzyme deficiency.

Phenylketonuria Emerging Drugs Profile

• JNT-517: Otsuka Pharmaceutical

JNT-517 is an oral, selective small molecule inhibitor targeting the Phe transporter SLC6A19, offering a novel therapeutic approach for the treatment of phenylketonuria (PKU). It acts at a unique, cryptic allosteric site to block the kidney reabsorption of phenylalanine (Phe), helping to lower elevated blood Phe levels. By targeting a key mechanism of Phe transport, JNT-517 has the potential to benefit individuals with PKU regardless of age or genetic profile. Its oral formulation makes it a convenient option for long-term management. Currently, the drug is in Phase III stage of its clinical trial for treatment of Phenylketonuria (PKU).

• RLF OD032: Relief Therapeutics Holding

RLF-OD032 is an innovative, highly concentrated liquid formulation of sapropterin dihydrochloride developed for oral use. It is intended for the treatment of phenylketonuria (PKU) in both adult and pediatric patients. The product is being submitted for US regulatory approval through the 505(b) (2) NDA pathway, supported by bioequivalence to a reference listed drug. If approved, RLF-OD032 would be the first and only ready-to-use, portable liquid sapropterin therapy. This unique formulation aims to improve PKU management by enhancing treatment adherence and patient quality of life. Currently, the drug is in Phase II stage of its clinical trial for treatment of Phenylketonuria (PKU).

• NGGT 002: Next Generation Gene Therapeutics

NGGT002 is an investigational gene therapy being developed by Next Generation Gene Therapeutics for the treatment of Phenylketonuria (PKU). NGGT002 has already demonstrated promising results in a completed proof-of-concept Investigator-Initiated Trial (IIT) in humans. The therapy is designed to address the underlying genetic cause of PKU by restoring normal metabolic function. Currently, the drug is being evaluated in Phase I/II stage of its clinical trial for treatment of Phenylketonuria (PKU).

The Phenylketonuria Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Phenylketonuria with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Phenylketonuria Treatment.
• Phenylketonuria Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Phenylketonuria Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Phenylketonuria market

Explore groundbreaking therapies and clinical trials in the Phenylketonuria Pipeline @ New Phenylketonuria Drugs

Phenylketonuria Companies

Otsuka Pharmaceutical, Relief Therapeutics Holding, Next Generation Gene Therapeutics, BioMarin Pharmaceutical, Tessera Therapeutics, Maze Therapeutics, Agios Pharmaceuticals, Alltrna, iECURE, SOM Biotech, YolTech and others.

Phenylketonuria Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Phenylketonuria Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Learn about new drugs, pipeline developments with DelveInsight’s expert analysis @ Phenylketonuria Market Drivers and Barriers

Scope of the Phenylketonuria Pipeline Report

• Coverage- Global
• Phenylketonuria Companies- Otsuka Pharmaceutical, Relief Therapeutics Holding, Next Generation Gene Therapeutics, BioMarin Pharmaceutical, Tessera Therapeutics, Maze Therapeutics, Agios Pharmaceuticals, Alltrna, iECURE, SOM Biotech, YolTech and others.
• Phenylketonuria Pipeline Therapies- Sepiapterin, PTC923, SYNB1618, SYNB1934, SAR444836, Kuvan®, Sapropterin dihydrochloride and others.
• Phenylketonuria Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Phenylketonuria Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Phenylketonuria Therapies and clinical trials @ Phenylketonuria Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Phenylketonuria: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Phenylketonuria– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. JNT-517: Otsuka Pharmaceutical
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Drug Name: Company Name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. RLF OD032: Relief Therapeutics Holding
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name : Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Phenylketonuria Key Companies
21. Phenylketonuria Key Products
22. Phenylketonuria- Unmet Needs
23. Phenylketonuria- Market Drivers and Barriers
24. Phenylketonuria- Future Perspectives and Conclusion
25. Phenylketonuria Analyst Views
26. Phenylketonuria Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP